AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21698811 — intervention group
Group type: EXPERIMENTAL
Intervention: Alverina citrate 60 mg with Simethicone 300 mg three times daily
Number of subjects: 409
Study 21698811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 21698811 — intervention group
Group type: EXPERIMENTAL
Intervention: Alverina citrate and Simethicone combination
Number of subjects: 409
Study 19233855 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 15532
Study 19233855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15532
Study 19233855 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet agents with highest tertile aspirin dose
Number of subjects: 15532
Study 19164787 — intervention group
Group type: EXPERIMENTAL
Intervention: Danqi Piantang Jiaonang (DJ)
Number of subjects: 605
Study 19164787 — intervention group
Group type: COMPARATOR
Intervention: Buchang Naoxintong Jiaonang (Control)
Number of subjects: 605
Study 15303131 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E (continuous epidural anesthesia)
Number of subjects: 30
Study 15303131 — intervention group
Group type: EXPERIMENTAL
Intervention: Group G+E (epidural anesthesia combined with general anesthesia)
Number of subjects: 30
Study 15303131 — intervention group
Group type: COMPARATOR
Intervention: Group G (general anesthesia)
Number of subjects: 30
Study 15303131 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 15303131 — intervention group
Group type: COMPARATOR
Intervention: Group G+E and Group G
Number of subjects: 30
Study 15303131 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E
Number of subjects: 30
Study 15303131 — intervention group
Group type: COMPARATOR
Intervention: Groups G+E and G
Number of subjects: 30
Study 15303131 — intervention group
Group type: COMPARATOR
Intervention: Group G and Group G+E
Number of subjects: 30
Study 12296500 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management
Number of subjects: 453
Study 12296500 — intervention group
Group type: COMPARATOR
Intervention: Non-case management
Number of subjects: 453
Study 9215059 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac-gentamicin
Number of subjects: 25
Study 9215059 — intervention group
Group type: COMPARATOR
Intervention: betamethasone-neomycin
Number of subjects: 25
Study 7805704 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam-beta-cyclodextrin (PBC)
Number of subjects: 225
Study 7805704 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 225
Study 7805704 — intervention group
Group type: COMPARATOR
Intervention: Tenoxicam
Number of subjects: 225
Study 3303294 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 276
Study 3303294 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 276
Study 3303294 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate and Cimetidine
Number of subjects: 276
Study 11772119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (12.5mg three times daily)
Number of subjects: 277
Study 11772119 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (20mg once daily plus two placebo capsules)
Number of subjects: 277
Study 11772119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 277
Study 11772119 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 277
Study 30165844 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly injection of exenatide
Number of subjects: 171
Study 30165844 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily injection of exenatide
Number of subjects: 171
Study 26550802 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy-to-pronounce anagrams
Number of subjects: 536
Study 26550802 — intervention group
Group type: COMPARATOR
Intervention: Hard-to-pronounce anagrams
Number of subjects: 536
Study 26550802 — intervention group
Group type: EXPERIMENTAL
Intervention: Short and long anagrams and nonanagrams
Number of subjects: 536
Study 26550802 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation timings from 4 down to 0.5 s
Number of subjects: 536
Study 24334348 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% dextrose (group 1)
Number of subjects: 25
Study 24334348 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (group 2)
Number of subjects: 25
Study 22441092 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvised traction splint
Number of subjects: 10
Study 22441092 — intervention group
Group type: COMPARATOR
Intervention: HARE traction splint
Number of subjects: 10
Study 22441092 — intervention group
Group type: COMPARATOR
Intervention: Sager traction splint
Number of subjects: 10
Study 22441092 — intervention group
Group type: COMPARATOR
Intervention: Faretech CT‐EMS traction splint
Number of subjects: 10
Study 20937187 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic 3-drug fixed-dose combination (3FDC) formulation of rifampicin
Number of subjects: 0
Study 20937187 — intervention group
Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 0
Study 20937187 — intervention group
Group type: COMPARATOR
Intervention: Comparison of test and reference products
Number of subjects: 0
Study 18782787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.1 microg/kg/min for 72 hours)
Number of subjects: 40
Study 18782787 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized perioperative therapy without fenoldopam)
Number of subjects: 40
Study 15762940 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning session with the first task before being tested in the second task.
Number of subjects: 28
Study 15762940 — intervention group
Group type: COMPARATOR
Intervention: Control group that only performed the second task.
Number of subjects: 28
Study 11952069 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous midazolam infusion (n = 21)
Number of subjects: 40
Study 11952069 — intervention group
Group type: COMPARATOR
Intervention: Diazepam infusion (n = 19)
Number of subjects: 40
Study 10624759 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equations for gas exchange, ventilatory and cardiovascular responses to maximum ramp-incremental cycle ergometry
Number of subjects: 120
Study 7723546 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus antibody 33B3.1 (n = 51)
Number of subjects: 101
Study 7723546 — intervention group
Group type: COMPARATOR
Intervention: Standard post‐transplantation immunosuppression (methotrexate plus cyclosporin; n = 50)
Number of subjects: 101
Study 1952306 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 mg methotrimeprazine (Levoprome, Nozinan)
Number of subjects: 74
Study 1952306 — intervention group
Group type: COMPARATOR
Intervention: 75 mg meperidine (Demerol) combined with 50 mg dimenhydrinate (Dramamine, Gravol)
Number of subjects: 74
Study 7035040 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times daily)
Number of subjects: 12
Study 30581039 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhang's guideline (intervention group)
Number of subjects: 11615
Study 30581039 — intervention group
Group type: COMPARATOR
Intervention: WHO partograph (control group)
Number of subjects: 11615
Study 28933712 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired-Set (PS) training
Number of subjects: 15
Study 28933712 — intervention group
Group type: COMPARATOR
Intervention: Traditional-Set (TS) training
Number of subjects: 15
Study 25644221 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (3.0g/day)
Number of subjects: 111
Study 25644221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 24352352 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS-targeted antiretrovirals (CNS-T)
Number of subjects: 59
Study 24352352 — intervention group
Group type: COMPARATOR
Intervention: non-CNS-targeted antiretrovirals (non-CNS-T)
Number of subjects: 59
Study 22849762 — intervention group
Group type: EXPERIMENTAL
Intervention: Moogoo Udder Cream®
Number of subjects: 0
Study 22849762 — intervention group
Group type: COMPARATOR
Intervention: Aqueous cream
Number of subjects: 0
Study 19384209 — intervention group
Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 11
Study 19384209 — intervention group
Group type: COMPARATOR
Intervention: Helmet with same settings
Number of subjects: 11
Study 19384209 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet with specific settings
Number of subjects: 11
Study 17545739 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine (20 mg/d)
Number of subjects: 350
Study 17545739 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 350
Study 15887425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/d) added to ongoing statin therapy
Number of subjects: 3030
Study 15887425 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ongoing statin therapy
Number of subjects: 3030
Study 11505962 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic power flosser
Number of subjects: 70
Study 11505962 — intervention group
Group type: COMPARATOR
Intervention: Manual dental floss
Number of subjects: 70
Study 9489626 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood progenitor cells (PBPC)
Number of subjects: 392
Study 9489626 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone marrow (BM) alone
Number of subjects: 392
Study 7908877 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium cromoglycate solution and oral oxatomide
Number of subjects: 100
Study 7908877 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo solution and oral oxatomide
Number of subjects: 100
Study 2970555 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG)
Number of subjects: 218
Study 2970555 — intervention group
Group type: COMPARATOR
Intervention: High-dose medroxyprogesterone acetate (MPA)
Number of subjects: 218
Study 2970555 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) and High-dose medroxyprogesterone acetate (MPA)
Number of subjects: 218
Study 30992107 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoMTA Plus
Number of subjects: 28
Study 30992107 — intervention group
Group type: COMPARATOR
Intervention: ProRoot MTA
Number of subjects: 28
Study 28154369 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham feeding with chewing gum 4 times a day after admission
Number of subjects: 204
Study 28154369 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment consistent with the guidelines for AP
Number of subjects: 204
Study 25735442 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (Ɛ4+, n=16)
Number of subjects: 107
Study 25735442 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group (Ɛ4-, n=35)
Number of subjects: 107
Study 25735442 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=56)
Number of subjects: 107
Study 23929375 — intervention group
Group type: EXPERIMENTAL
Intervention: Luting and Lining (S3)
Number of subjects: 80
Study 23929375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Cem (S2)
Number of subjects: 80
Study 23929375 — intervention group
Group type: EXPERIMENTAL
Intervention: Luting and Lining (S1)
Number of subjects: 80
Study 23929375 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink II (S1)
Number of subjects: 80
Study 23929375 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink II (S2)
Number of subjects: 80
Study 23929375 — intervention group
Group type: EXPERIMENTAL
Intervention: Rely X ARC (S3)
Number of subjects: 80
Study 21464481 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid THR
Number of subjects: 157
Study 21464481 — intervention group
Group type: COMPARATOR
Intervention: Cementless THR
Number of subjects: 157
Study 19233339 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention-based rehearsal (not specified in dosage or duration)
Number of subjects: 0
Study 19233339 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation of processing at the memorized location (not specified in dosage or duration)
Number of subjects: 0
Study 17118191 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient mix (288 mg vitamin E, 375 mg vitamin C, 12 mg beta-carotene, 15 mg zinc/day)
Number of subjects: 138
Study 17118191 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum concentrate (1.2 g/d)
Number of subjects: 138
Study 17118191 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of colostrum and micronutrient mix
Number of subjects: 138
Study 17118191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 14711545 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 fertile patients)
Number of subjects: 35
Study 14711545 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation failure group (35 patients)
Number of subjects: 35
Study 10735604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisk Fatigue Severity Score (FFSS)
Number of subjects: 58
Study 10735604 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonhepatic disease patients)
Number of subjects: 58
Study 8612408 — intervention group
Group type: COMPARATOR
Intervention: Dopamine infusion continued
Number of subjects: 15
Study 8612408 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion discontinued
Number of subjects: 15
Study 8612408 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH administration (200 micrograms, two consecutive doses)
Number of subjects: 15
Study 8612408 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH administration (200 micrograms, two consecutive doses) after dopamine withdrawal
Number of subjects: 15
Study 1424007 — intervention group
Group type: EXPERIMENTAL
Intervention: Photopheresis
Number of subjects: 16
Study 1424007 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 16
Study 2859861 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg for 4 weeks)
Number of subjects: 0
Study 2859861 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (low dosage)
Number of subjects: 0
Study 2859861 — intervention group
Group type: EXPERIMENTAL
Intervention: Other beta-adrenoceptor blockers (acebutolol, penbutolol, pindolol)
Number of subjects: 0
Study 2859861 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade (general)
Number of subjects: 0
Study 30797394 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX) implants
Number of subjects: 29
Study 30797394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 27876186 — intervention group
Group type: EXPERIMENTAL
Intervention: IOMRI (Intra-operative Magnetic Resonance Imaging), n=25
Number of subjects: 50
Study 27876186 — intervention group
Group type: COMPARATOR
Intervention: 2D-F (Two Dimensional Fluoroscopy), n=25
Number of subjects: 50
Study 26691247 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC 300 mg + Albendazole 400 mg sequential administration
Number of subjects: 146
Study 26691247 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC 300 mg + Albendazole 400 mg co-administration
Number of subjects: 146
Study 26691247 — intervention group
Group type: COMPARATOR
Intervention: DEC 300 mg + Doxycycline 100 mg co-administration
Number of subjects: 146
Study 26691247 — intervention group
Group type: COMPARATOR
Intervention: Control regimen DEC 300 mg
Number of subjects: 146
Study 24422264 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal hand-off process (IPASS the BATON)
Number of subjects: 107
Study 24422264 — intervention group
Group type: COMPARATOR
Intervention: Informal hand-off process
Number of subjects: 107
Study 20925688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine
Number of subjects: 24
Study 20925688 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine
Number of subjects: 24
Study 19205853 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect response (IDR) model
Number of subjects: 0
Study 19205853 — intervention group
Group type: EXPERIMENTAL
Intervention: Transit (TM) model
Number of subjects: 0
Study 19205853 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse Bateman (IBM) model
Number of subjects: 0
Study 17522765 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% diltiazem ointment
Number of subjects: 90
Study 17522765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% glyceryl trinitrate (GTN) ointment
Number of subjects: 90
Study 17522765 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 15595331 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs) - phenobarbital, phenytoin, valproic acid
Number of subjects: 5
Study 15595331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 12431962 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) followed by involved-field radiotherapy (arm B)
Number of subjects: 312
Study 12431962 — intervention group
Group type: COMPARATOR
Intervention: CHOP + etoposide followed by involved-field radiotherapy (arm A)
Number of subjects: 312
Study 12431962 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for all patients
Number of subjects: 312
Study 12431962 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free survival
Number of subjects: 312
Study 12431962 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse in arm B
Number of subjects: 312
Study 12431962 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary neoplasia
Number of subjects: 312
Study 10630160 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional irradiation (79 patients)
Number of subjects: 240
Study 10630160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated irradiation (81 patients)
Number of subjects: 240
Study 10630160 — intervention group
Group type: COMPARATOR
Intervention: Control group (80 patients)
Number of subjects: 240
Study 8611059 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsessive Compulsive Drinking Scale (OCDS)
Number of subjects: 41
Study 8611059 — intervention group
Group type: EXPERIMENTAL
Intervention: OCDS
Number of subjects: 41
Study 2007102 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (0.7, 1.85, and 3.7 mg/kg) infused over 15, 45, and 75 minutes
Number of subjects: 10
Study 2007102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6180687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of up to 300 mg of urushiol over three to six months
Number of subjects: 21
Study 6180687 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 21
Study 6180687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of urushiol
Number of subjects: 21
Study 2996444 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate solution
Number of subjects: 94
Study 2996444 — intervention group
Group type: COMPARATOR
Intervention: WHO oral rehydration solution
Number of subjects: 94
Study 28229572 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (200 mg per day for 4 weeks)
Number of subjects: 21
Study 28229572 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 mg per day for 4 weeks)
Number of subjects: 21
Study 26507904 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography care pathway
Number of subjects: 1368
Study 26507904 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 1368
Study 26507904 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (negative result)
Number of subjects: 1368
Study 23871132 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate (1 g Ca as pentacalcium hydroxy-triphosphate)
Number of subjects: 10
Study 23871132 — intervention group
Group type: COMPARATOR
Intervention: Placebo bread
Number of subjects: 10
Study 22221724 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 26
Study 22221724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22221724 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram and Placebo
Number of subjects: 26
Study 20831671 — intervention group
Group type: EXPERIMENTAL
Intervention: Green banana-supplemented diet
Number of subjects: 2968
Study 20831671 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2968
Study 18296081 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting wrap (1.6 microg/mm²) placed around the distal graft anastomosis
Number of subjects: 109
Study 18296081 — intervention group
Group type: COMPARATOR
Intervention: Control group (graft implanted alone)
Number of subjects: 109
Study 16167790 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 microg x kg(‐1) and famotidine 20 mg
Number of subjects: 32
Study 16167790 — intervention group
Group type: COMPARATOR
Intervention: Control group received oral famotidine alone
Number of subjects: 32
Study 12797394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin prophylaxis (200 mg/2x12h)
Number of subjects: 25
Study 12797394 — intervention group
Group type: COMPARATOR
Intervention: Control (standard perioperative antibiotic prophylaxis with 2 g cefotiam)
Number of subjects: 25
Study 10782653 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (50 mg)
Number of subjects: 29133
Study 10782653 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene (20 mg)
Number of subjects: 29133
Study 10782653 — intervention group
Group type: EXPERIMENTAL
Intervention: both agents
Number of subjects: 29133
Study 10782653 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29133
Study 8876883 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation with 25 Gy in five cycles during 5-7 days (RT+ group)
Number of subjects: 557
Study 8876883 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (RT- group)
Number of subjects: 557
Study 1793784 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms misoprostol b.d. after meals
Number of subjects: 12
Study 1793784 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms misoprostol b.d. before meals
Number of subjects: 12
Study 1793784 — intervention group
Group type: COMPARATOR
Intervention: Placebo before and after meals
Number of subjects: 12
Study 6186165 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone nasal spray
Number of subjects: 0
Study 31442336 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in the overnight‐fasted state (n = 15)
Number of subjects: 30